Advertisement
A live webcast of Mr. Rieder's presentation can be accessed on Cardiome'swebsite at www.cardiome.com. A replay of the webcast will be posted after thepresentation and will be available until October 19, 2007.
Advertisement
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused cardiovascular drug developmentcompany with two late-stage clinical drug programs focused on atrialarrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, anengineered analog of recombinant human activated Protein C, and a pre-clinicalprogram directed at improving cardiovascular function.
Vernakalant (iv) is the intravenous formulation of an investigational drugbeing evaluated for the acute conversion of atrial fibrillation (AF). Positivetop-line results from two pivotal Phase 3 trials for vernakalant (iv), calledACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome'sco-development partner Astellas Pharma US, Inc. submitted a New DrugApplication for vernakalant (iv) in December 2006. Positive top-line resultsfrom an additional Phase 3 study evaluating patients with post-operativeatrial arrhythmia, called ACT 2, were released in June 2007. An open-labelsafety study evaluating recent-onset AF patients, called ACT 4, has completed.
Vernakalant (oral) is being investigated as a chronic-use oral drug forthe maintenance of normal heart rhythm following termination of AF. Cardiomeannounced positive results from a Phase 2a pilot study for vernakalant (oral)in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.
In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC forall indications. Cardiome intends to initially develop GED-aPC in cardiogenicshock, a life-threatening form of acute circulatory failure due to cardiacdysfunction, which is a leading cause of death for patients hospitalizedfollowing a heart attack.
Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQNational Market (CRME).
Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995 or forward-looking information under applicable Canadian securitieslegislation that may not be based on historical fact, including withoutlimitation statements containing the words "believe", "may", "plan", "will","estimate", "continue", "anticipate", "intend", "expect" and similarexpressions. Such forward-looking statements or information involve known andunknown risks, uncertainties and other factors that may cause our actualresults, events or developments, or industry results, to be materiallydifferent from any future results, events or developments expressed or impliedby such forward-looking statements or information. Such factors include, amongothers, our stage of development, lack of product revenues, additional capitalrequirements, risk associated with the completion of clinical trials andobtaining regulatory approval to market our products, the ability to protectour intellectual property, dependence on collaborative partners and theprospects for negotiating additional corporate collaborations or licensingarrangements and their timing. Specifically, certain risks and uncertaintiesthat could cause such actual events or results expressed or implied by suchforward-looking statements and information to differ materially from anyfuture events or results expressed or implied by such statements andinformation include, but are not limited
